Juxtapid

Chemical Namelomitapide
Dosage FormCapsule (oral; 5 mg, 10 mg, 20 mg)
Drug ClassInhibitors
SystemBlood
CompanyAmryt Pharmaceuticals
Approval Year2012

Indication

  • Indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)
Last updated on 6/16/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Juxtapid (lomitapide) Prescribing Information.2012Amyrt Pharmaceuticals DAC., Dublin, Ireland